Davis Polk advised Goldman, Sachs & Co. and J.P. Morgan Securities LLC as joint book-running managers on a Rule 144A offering by Isis Pharmaceuticals, Inc. of $201.25 million aggregate principal amount of 2.75% convertible senior notes due 2019.
Headquartered in Carlsbad, California, Isis is the leading company in antisense drug discovery and development, exploiting a novel drug discovery platform to generate a broad pipeline of first-in-class drugs.
The Davis Polk corporate team included partner Alan F. Denenberg and associates Jeffrey Gould and Nicholas J. Dashman. The tax team included partner Rachel D. Kleinberg and law clerk Isaac MacDonald (New York office). Associates Emma Maconick and Daniel Ray (New York office) provided intellectual property advice. Elizabeth J. Gordon was the legal assistant on the transaction. Except as notes above, all members of the Davis Polk team are based in the Menlo Park office.
Related Posts:
- Davis Polk – Isis Pharmaceuticals, Inc. Common Stock Offering
- Davis Polk – Netflix, Inc. Common Stock Offering
- Davis Polk – Intel Corporation $5 Billion Notes Offering
- Davis Polk – NVIDIA Corporation $1.5 Billion Convertible Senior Notes Offering
- Davis Polk – Accuray Incorporated $100 Million Convertible Senior Notes Offering
